Assessment of Efficacy and Safety of UK-390,957 in Men With Premature Ejaculation
A Phase 2b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study to Assess the Efficacy and Safety of Oral UK-390,957 in Men With Premature Ejaculation
1 other identifier
interventional
460
1 country
51
Brief Summary
To determine whether UK-390,957 is an effective and safe treatment for premature ejaculation.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_2
Started Aug 2004
Shorter than P25 for phase_2
51 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 1, 2004
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2005
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2005
CompletedFirst Submitted
Initial submission to the registry
August 30, 2005
CompletedFirst Posted
Study publicly available on registry
September 2, 2005
CompletedNovember 7, 2012
November 1, 2012
10 months
August 30, 2005
November 5, 2012
Conditions
Outcome Measures
Primary Outcomes (1)
Assessment of efficacy and safety
Secondary Outcomes (1)
Assessment of Quality of Sexual Life
Interventions
Eligibility Criteria
You may qualify if:
- Premature ejaculation as defined by DSM-IV
You may not qualify if:
- History of erectile dysfunction
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Pfizerlead
Study Sites (51)
Pfizer Investigational Site
Tucson, Arizona, United States
Pfizer Investigational Site
Anaheim, California, United States
Pfizer Investigational Site
Atherton, California, United States
Pfizer Investigational Site
Beverly Hills, California, United States
Pfizer Investigational Site
Laguna Woods, California, United States
Pfizer Investigational Site
Newport Beach, California, United States
Pfizer Investigational Site
Redwood City, California, United States
Pfizer Investigational Site
San Diego, California, United States
Pfizer Investigational Site
Tarzana, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
Aurora, Colorado, United States
Pfizer Investigational Site
Waterbury, Connecticut, United States
Pfizer Investigational Site
Aventura, Florida, United States
Pfizer Investigational Site
New Port Richey, Florida, United States
Pfizer Investigational Site
Pembroke Pines, Florida, United States
Pfizer Investigational Site
Evansville, Indiana, United States
Pfizer Investigational Site
Fort Wayne, Indiana, United States
Pfizer Investigational Site
Indianapolis, Indiana, United States
Pfizer Investigational Site
Michigan City, Indiana, United States
Pfizer Investigational Site
Lexington, Kentucky, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
Metairie, Louisiana, United States
Pfizer Investigational Site
Milford, Massachusetts, United States
Pfizer Investigational Site
Saint Clair Shores, Michigan, United States
Pfizer Investigational Site
Minneapolis, Minnesota, United States
Pfizer Investigational Site
Southhaven, Mississippi, United States
Pfizer Investigational Site
Kansas City, Missouri, United States
Pfizer Investigational Site
Reno, Nevada, United States
Pfizer Investigational Site
Edison, New Jersey, United States
Pfizer Investigational Site
New Brunswick, New Jersey, United States
Pfizer Investigational Site
Voorhees Township, New Jersey, United States
Pfizer Investigational Site
Albany, New York, United States
Pfizer Investigational Site
Endwell, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
West Seneca, New York, United States
Pfizer Investigational Site
Williamsville, New York, United States
Pfizer Investigational Site
Charlotte, North Carolina, United States
Pfizer Investigational Site
Durham, North Carolina, United States
Pfizer Investigational Site
Beachwood, Ohio, United States
Pfizer Investigational Site
Tulsa, Oklahoma, United States
Pfizer Investigational Site
Germantown, Tennessee, United States
Pfizer Investigational Site
Knoxville, Tennessee, United States
Pfizer Investigational Site
Memphis, Tennessee, United States
Pfizer Investigational Site
Milan, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Fort Worth, Texas, United States
Pfizer Investigational Site
Houston, Texas, United States
Pfizer Investigational Site
Plano, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Tacoma, Washington, United States
Pfizer Investigational Site
Milwaukee, Wisconsin, United States
Related Links
Study Officials
- STUDY DIRECTOR
Pfizer CT.gov Call Center
Pfizer
Study Design
- Study Type
- interventional
- Phase
- phase 2
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 30, 2005
First Posted
September 2, 2005
Study Start
August 1, 2004
Primary Completion
June 1, 2005
Study Completion
June 1, 2005
Last Updated
November 7, 2012
Record last verified: 2012-11